Prevents EFAD. Sold as Intralipid 10%, Intralipid 20%, Soyacal 10%, Travamulsion 10%, Travamulsion 20% and 7 more. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 12 applications for Soybean Oil (sold as Intralipid 10%, Intralipid 20%, Soyacal 10% and others), first approved Oct 7, 1975, with 0 new uses approved and 0 published complete response letters.
| Green Banana Added Diet on Prolong Diarrhea in 6-59 Months Old Children (GB in ProD)Diarrhoeal Disease, Prolonged Diarrhea · International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 2 | Not yet recruiting | Sep 30, 2026 |
| Replacing Meat With Legumes in a Mediterranean DietHealthy Adult Participants · Universidad Francisco de Vitoria | Not applicable | Not yet recruiting | Sep 29, 2026 |
| Elucidating the Effect of Dietary Stearic Acid on the Regional Heterogeneity of the Gut Microbiome and Metabolome: Focus on Bile Acid Metabolism (SAMPill Study)CVD Risk · Tufts University | Not applicable | Not yet recruiting | Aug 17, 2026 |
| Impact of a Novel Functional Snack on Perimenopausal Symptoms and Well-beingPerimenopause, Perimenopause-Related Depression · King's College London | Not applicable | Recruiting | May 20, 2026 |
| Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer PatientsHead and Neck Squamous Cell Carcinoma, Locally Advanced Rectal Cancer · Fondazione del Piemonte per l'Oncologia | Not applicable | Recruiting | Apr 7, 2026 |
| Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRacticeMajor Depressive Disorder (MDD) · National Science and Technology Council, Taiwan | Not applicable | Recruiting | Mar 10, 2026 |
| Omega-3 Supplementation in Systemic Lupus ErythematosusLupus Erythematosus, Systemic · University of Sao Paulo | Not applicable | Not yet recruiting | Feb 6, 2026 |
| Omega-3, Autism Spectrum Disorder (ASD)ASD · China Medical University Hospital | Not applicable | Recruiting | Jan 26, 2026 |
| Oct 7, 1975 | Intralipid 10%NDA 17643 · New dosage form | Fresenius | 62 | Discontinued |
| Jan 23, 1981 | Intralipid 20%NDA 18449 · New dosage form | Fresenius | 36 | Marketed |
| Feb 26, 1982 | Travamulsion 10%NDA 18660 · New formulation or manufacturer | Baxter Hlthcare | 4 | Discontinued |
| Jun 29, 1983 | Soyacal 10%NDA 18465 · New formulation or manufacturer | Alpha Thera | 14 | Discontinued |
| Jun 29, 1983 | Soyacal 20%NDA 18786 · New formulation or manufacturer | Alpha Thera | 15 | Discontinued |
| Sep 24, 1984 | Liposyn Iii 10%NDA 18969 · New formulation or manufacturer | Hospira | 8 | Discontinued |
| Sep 25, 1984 | Liposyn Iii 20%NDA 18970 · New formulation or manufacturer | Hospira | 8 | Discontinued |
| May 28, 1993 | Nutrilipid 10%, Nutrilipid 20%NDA 19531 · New formulation or manufacturer | B Braun | 7 | Marketed |
| Dec 30, 1993 | Intralipid 30%NDA 19942 · New dosage form | Fresenius | 12 | Marketed |
| Aug 7, 1996 | Intralipid 20%NDA 20248 · New dosage form | Fresenius | 14 | Marketed |
| Jan 13, 1998 | Liposyn Iii 30%NDA 20181 · New dosage form | Hospira | 1 | Discontinued |
| — | Travamulsion 20%NDA 18758 | Baxter Hlthcare | 5 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Fresenius
Baxter Hlthcare